论文部分内容阅读
目的比较酸性成纤维细胞生长因子(acid fibroblast growth factor,aFGF或FGF-1)在正常乳腺组织、乳腺良性肿瘤及乳腺癌中的表达差异,探讨FGF-1与乳腺癌血管生成的关系。方法应用免疫组织化学(immunohistochemistry,IHC)SP法检测FGF-1在40例乳腺癌组织、12例良性乳腺肿瘤组织及12例正常乳腺组织中的表达情况;以CD34抗体标记血管内皮细胞CD34抗原行乳腺癌组织微血管密度(microvessel density,MVD)计数。结果 FGF-1在40例乳腺癌中的阳性表达率(57.5%,23/40)显著高于12例乳腺良性肿瘤组织中阳性表达率(16.7%,2/12)以及正常乳腺组织阳性表达率(0,0/12),差异有统计学意义(P<0.05);良性肿瘤组FGF-1表达率和正常乳腺组织比较无统计学意义(P>0.05)。40例乳腺癌组织MVD计数为(70.17±29.33)个/HP,在23例FGF-1阳性组中MVD计数为(89.48±23.23)个/HP,显著高于17例阴性组(44.06±12.53)个/HP,差异有统计学意义(P<0.05)。结论 FGF-1可能参与乳腺癌微血管生成。
Objective To compare the expression of aFGF or FGF-1 in normal breast tissue, breast benign tumor and breast cancer, and to explore the relationship between FGF-1 and angiogenesis in breast cancer. Methods The expression of FGF-1 in 40 cases of breast cancer tissues, 12 cases of benign breast tumor tissues and 12 cases of normal breast tissues was detected by immunohistochemistry (IHC) SP method. CD34 antibody was used to label CD34 antigen of vascular endothelial cells Breast cancer tissue microvessel density (MVD) count. Results The positive expression rates of FGF-1 in 40 cases of breast cancer (57.5%, 23/40) were significantly higher than those in 12 cases of benign breast tumor (16.7%, 2/12) and in normal breast tissues (0, 0/12), the difference was statistically significant (P <0.05). There was no significant difference in the expression of FGF-1 between benign tumor and normal breast (P> 0.05). The MVD count in 40 cases of breast cancer was (70.17 ± 29.33) / HP, the MVD count was (89.48 ± 23.23) / HP in 23 cases of FGF-1 positive group, which was significantly higher than that in 17 cases (44.06 ± 12.53) / HP, the difference was statistically significant (P <0.05). Conclusion FGF-1 may be involved in breast microvascular angiogenesis.